INS and metabolic dysfunction-associated steatohepatitis: Nevertheless, there are several drugs currently at various stages of development for the therapy of NASH, possessing anti-inflammatory activity, improve insulin resistance, reduce de novo lipogenesis, modulate lipid transport or oxidation, or evolve anti-apoptotic effects (Tacke and Weiskirchen, 2018).